Pharmacogenomics of 17‐alpha hydroxyprogesterone caproate for recurrent preterm birth: a case–control study
Manuck T, Watkins W, Esplin, Biggio J, Bukowski R, Parry S, Zhan H, Huang H, Andrews W, Saade G, Sadovsky Y, Reddy U, Ilekis J, Yandell M, Varner M, Jorde L, Research T. Pharmacogenomics of 17‐alpha hydroxyprogesterone caproate for recurrent preterm birth: a case–control study. BJOG An International Journal Of Obstetrics & Gynaecology 2017, 125: 343-350. PMID: 28139890, DOI: 10.1111/1471-0528.14485.Peer-Reviewed Original ResearchConceptsRecurrent preterm birthPreterm birthSuccessful prolongationDefinition ADefinition BSingleton spontaneous preterm birthSpontaneous preterm birthTertiary care centerCase-control studyWhole-exome sequencingUntreated pregnanciesGestational ageHydroxyprogesterone caproateSignificant prolongationPregnancyExome sequencingProlongationWomenPharmacogenetic genesBirthGene ontology pathwaysIntegrated DiscoveryOntology pathwaysNovel analytic approach